Ludiflash® is a combined filler, binder and disintegrant, designed to dissolve in the mouth within seconds.
Ludiflash® is a combined filler, binder and disintegrant, designed to dissolve in the mouth within seconds.
Ludiflash® comprises the following ingredients: 90 percent Mannitol, a fast-dissolving filler with a mildly sweet taste; 5 percent Kollidon® CL-SF (crospovidone), a superior tablet disintegrant that is effective even with very little liquid; and 5 percent Kollicoat® SR 30 D (polyvinyl acetate), a hydrophobic binder. Each component complies with all leading pharmacopoeia monographs. Plus, the fast-disintegrating, fast-acting formulations created with Ludiflash® offer an exceptionally smooth and creamy mouthfeel – enhancing patient compliance.
Ludiflash® delivers tangible benefits to manufacturers, exhibiting good flowability, compressibility and stability. The compound’s low hygroscopicity ensures the stability of the active ingredient and of the tablet itself.
Ludiflash® is suitable for direct compression and roller compaction, and can be deployed in wet-granulation processes. Blends can be processed on standard tableting machines or used in the form of granulate or powder. When a standard tableting process is used, Ludiflash® ensures excellent uniformity, even at high speeds: creating compact and highly porous tablets that offer exceptional hardness and low friability, making them suitable for polyethylene containers and push-through blisters.
www.pharma-ingredients.basf.com/Ludiflash/Home.aspx
pharma-ingredients@basf.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.